Evidence map›Paper›PMID 28611394›Full record

ArticleInternational journal of obesity (2005)2017

Identification of the ectoenzyme CD38 as a marker of committed preadipocytes.

A Carrière, Y Jeanson, J-A Côté, C Dromard, A Galinier, S Menzel, C Barreau, S Dupuis-Coronas, E Arnaud, A Girousse and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of obesity (2005), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Immunoregulation in cancer-associated cachexia.Journal of advanced research · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 3 countries.

A CarrièreSTROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm, UPS, Toulouse, France.
Y JeansonSTROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm, UPS, Toulouse, France.
J-A CôtéCentre de Recherche de l'IUCPQ, Quebec, QC, Canada.
C DromardSTROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm, UPS, Toulouse, France.
A GalinierSTROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm, UPS, Toulouse, France.
S MenzelInstitute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
C BarreauSTROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm, UPS, Toulouse, France.
S Dupuis-CoronasSTROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm, UPS, Toulouse, France.
E ArnaudSTROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm, UPS, Toulouse, France.
A GirousseSTROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm, UPS, Toulouse, France.
V CuminettiSTROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm, UPS, Toulouse, France.
J PaupertSTROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm, UPS, Toulouse, France.
B CousinSTROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm, UPS, Toulouse, France.
C SengenesSTROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm, UPS, Toulouse, France.
F Koch-NolteInstitute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
A TchernofCentre de Recherche de l'IUCPQ, Quebec, QC, Canada.
L CasteillaSTROMALab, Université de Toulouse, CNRS ERL 5311, EFS, INP-ENVT, Inserm, UPS, Toulouse, France.
Centre National de la Recherche Scientifique · FRÉcole Nationale Vétérinaire de Toulouse · FRUniversité Fédérale de Toulouse Midi-Pyrénées · FRInserm · FRInstitut universitaire de cardiologie et de pneumologie de Québec · CAUniversité Toulouse III - Paul Sabatier · FRUniversity Medical Center Hamburg-Eppendorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesCharacterisation of the adipocyte cellular lineage is required for a better understanding of white adipose tissue homoeostasis and expansion. Although several studies have focused on the phenotype of the most immature adipocyte progenitors, very few tools exist to identify committed cells. In haematopoiesis, the CD38 ectoenzyme is largely used to delineate various stages of stem cell lineage commitment. We hypothesise that this marker could be used to identify committed preadipocytes.

methodsComplementary strategies including flow cytometry, cell-sorting approaches, immunohistochemistry and primary cultures of murine adipose progenitors isolated from different fat pads of control or high-fat diet exposed C57BL/6 J mice were used to determine the molecular expression profile, proliferative and differentiation potentials of adipose progenitors expressing the CD38 molecule.

resultsWe demonstrate here that a subpopulation of CD45

conclusionsTogether, these data demonstrate that CD38 represents a new marker that identifies committed preadipocytes as CD45

Indexed as

Cell DifferentiationCell LineageAdipocytesAdipose Tissue, WhiteADP-ribosyl Cyclase 1AnimalsBiomarkersCells, CulturedDiet, High-FatDisease Models, AnimalFlow CytometryImmunohistochemistryMaleMembrane GlycoproteinsMetabolic SyndromeMiceADP-ribosyl Cyclase 1BiomarkersCd38 protein, mouseMembrane Glycoproteins

Identifiers

PMID28611394
OpenAlexW2625607969

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.